阿斯利康（中国）：以全病程诊疗一体化服务推动社会创新

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Nebulizer 50%
• Prostate Cancer 50%
• Gastroenterology 50%
• Combination Therapy 50%
• Thorax Pain 50%
• Budesonide 50%
• Respiratory Tract Disease 50%
• Cardiovascular Disease 50%

Social Sciences

• Diseases 100%
• Industrial Sector 16%
• Social Benefit 16%

Economics, Econometrics and Finance

• Return on Investment 50%